Skip to main content
    T

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.88
    -0.13 (-4.32%)

    Market Cap: $58.49M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tonix Pharmaceuticals Holding Corp (TNXP) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tonix Pharmaceuticals Holding (TNXP) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Tonix Pharmaceuticals Holding reported EPS of -$2.89, below the -$2.51 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/40)
    Avg Surprise
    -2.22%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.41
    Range-$2.45 - -$2.39
    8 analysts
    Revenue Consensus
    $20.70M
    Range$16.17M - $24.15M
    8 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$2.42
    Range-$2.42 - -$2.42
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$2.20-10.3%
    60d ago-$2.20-10.3%
    30d ago-$2.20-10.3%
    7d ago-$2.20-10.3%
    Current-$2.42
    Revenue Consensus
    $23.25M
    Range$17.50M - $29.00M
    2 analysts

    Next Report

    TNXP has an expected report date of Mar 10, 2027.

    TNXP Earnings Call

    The latest TNXP earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, TNXP beat 15, missed 15 and matched 10. Revenue for the quarter ended Sep 30, 2026 was $17.23M, up 423.7% from $3.29M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$2.89-$2.51N/A-15.14%MissN/A31 up, 0 downNov 9, 2026$17.23M
    Jun 30, 2026-$2.44-$2.71-$2.76 - -$2.48+9.96%BeatN/A20 up, 1 downAug 10, 2026$13.54M
    Mar 31, 2026-$2.93-$2.54-$2.98 - -$2.10-15.35%MissN/A20 up, 1 downMay 11, 2026$6.88M
    Dec 31, 2025-$3.98-$3.19N/A-24.82%MissN/A11 up, 0 downMar 12, 2026$5.39M
    Sep 30, 2025-$3.70-$2.75-$2.75 - -$2.75-34.55%MissN/A11 up, 0 downNov 10, 2025$3.29M
    Jun 30, 2025-$4.00-$1.88-$1.88 - -$1.88-112.77%MissN/A11 up, 0 downAug 11, 2025$2.00M
    Mar 31, 2025-$2.64-$3.09-$3.09 - -$3.09+14.56%BeatN/A11 up, 0 downMay 12, 2025$2.43M
    Dec 31, 2024-$9.77-$3.91N/A-149.80%MissN/AN/A0 up, 0 downMar 18, 2025$2.58M
    Sep 30, 2024-$25.56-$736.00-$736.00 - -$40.00+96.53%BeatN/A30 up, 0 downNov 12, 2024$2.82M
    Jun 30, 2024-$464.22-$720.00-$736.00 - -$118.00+35.52%BeatN/A31 up, 0 downAug 16, 2024$2.21M
    Mar 31, 2024-$576.00-$1,136.00-$1,506.41 - -$993.59+49.30%BeatN/A20 up, 0 downApr 1, 2024$2.48M
    Dec 31, 2023-$0.86-$1.64-$1.83 - -$1.46+47.56%BeatN/A30 up, 0 downMar 25, 2024$3.78M
    Sep 30, 2023-$5,856.00-$4,496.00-$5,320.51 - -$3,750.00-30.25%MissN/A31 up, 0 downNov 9, 2023$3.99M
    Jun 30, 2023-$8,576.00-$5,264.00N/A-62.92%MissN/A21 up, 0 downAug 10, 2023N/A
    Mar 31, 2023-$10,400.00-$11,400.00-$11,418.27 - -$8,012.82+8.77%BeatN/A20 up, 0 downMay 8, 2023N/A
    Dec 31, 2022-$0.56-$0.86-$1.41 - -$0.54+34.88%BeatN/A30 up, 0 downMar 13, 2023N/A
    Sep 30, 2022-$13,800.00-$26,400.00-$26,442.31 - -$14,423.08+47.73%BeatN/A20 up, 0 downNov 7, 2022N/A
    Jun 30, 2022-$24,400.00-$28,600.00N/A+14.69%BeatN/AN/A0 up, 0 downAug 8, 2022N/A
    Mar 31, 2022-$32,000.00-$32,000.00-$32,102.65 - -$25,682.120.00%In lineN/A30 up, 0 downMay 9, 2022N/A
    Dec 31, 2021-$2.24-$1.92-$2.24 - -$1.60-16.67%MissN/A20 up, 0 downMar 14, 2022N/A
    Sep 30, 2021-$32,000.00-$44,800.00N/A+28.57%BeatN/A2N/ANov 8, 2021N/A
    Jun 30, 2021-$44,800.00-$38,400.00N/A-16.67%MissN/A2N/AAug 9, 2021N/A
    Mar 31, 2021-$44,800.00-$38,400.00-$38,523.18 - -$32,102.65-16.67%MissN/A2N/AMay 10, 2021N/A
    Dec 31, 2020-$3.20-$2.40-$2.56 - -$2.24-33.33%MissN/A2N/AMar 15, 2021$2.91M
    Sep 30, 2020-$57,600.00-$70,400.00N/A+18.18%BeatN/A2N/ANov 9, 2020N/A
    Jun 30, 2020-$147,200.00-$134,400.00N/A-9.52%MissN/A2N/AAug 10, 2020N/A
    Mar 31, 2020-$9.60-$10.08-$13.46 - -$6.73+4.76%BeatN/A2N/AMay 12, 2020N/A
    Dec 31, 2019-$1,000,000.00-$953,600.00-$1,123,592.62 - -$789,725.10-4.87%MissN/A2N/AMar 24, 2020N/A
    Sep 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A2N/ANov 8, 2019N/A
    Jun 30, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A3N/AAug 12, 2019N/A
    Mar 31, 2019-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A2N/AMay 13, 2019N/A
    Dec 31, 2018-$1,952.00-$1,172.27-$1,250.00 - -$1,041.67-66.51%MissN/A3N/AMar 18, 2019N/A
    Sep 30, 2018-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 9, 2018N/A
    Jun 30, 2018-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A4N/AAug 13, 2018N/A
    Mar 31, 2018-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/A1N/AMay 14, 2018N/A
    Dec 31, 2017-$2,176.00-$2,480.00-$2,564.10 - -$2,403.85+12.26%BeatN/A2N/AMar 12, 2018N/A
    Sep 30, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/ANov 7, 2017N/A
    Jun 30, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AAug 14, 2017N/A
    Mar 31, 2017-$1,000,000.00-$1,000,000.00N/A0.00%In lineN/AN/AN/AApr 17, 2017N/A
    Dec 31, 2016-$2.97-$130.00N/A+97.72%BeatN/AN/AN/AMar 3, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$14.32, after -$1,075.55 the year before. It was -$3,000,002.97 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$14.32N/A
    Dec 31, 2024-$1,075.55N/A
    Dec 31, 2023-$24,832.86N/A
    Dec 31, 2022-$70,200.56N/A
    Dec 31, 2021-$121,602.24N/A
    Dec 31, 2020-$204,812.80N/A
    Dec 31, 2019-$4,000,000.00N/A
    Dec 31, 2018-$3,001,952.00N/A
    Dec 31, 2017-$3,002,176.00N/A
    Dec 31, 2016-$3,000,002.97N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,97510
    2026Q2Jun 30, 20264,9718

    2026Q3 Earnings Call

    Opening remarks

    Deborah Elson Head of Investor Relations Thank you, operator, and good morning, everyone. Thank you for joining us to discuss Tonix Pharmaceuticals' Third Quarter 2026 Financial Results and Operational Highlights. Before we begin, I would like to refer you to the forward-looking statements disclaimers on Slide 2. Any statements made on today's call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA and any of our approved products, uncertainties of patent protection and litigation, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations, risks related to the timing and progress of clinical development of our product candidates, our need for additional financing, uncertainties of government or third-party payer reimbursement, limited research and development efforts and dependence upon third parties, and substantial competition. These risks are described more fully in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2025, and our subsequent quarterly reports on Form 10-Q. Tonix undertakes no obligation to update or revise any forward-looking statements, except as required by law. Joining me on today's call are Dr. Seth Lederman, Chief Executive Officer; Thomas Englese, Chief Commercial Officer; and Bradley Saenger, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. With that, I will turn the call over to Seth. Seth?

    Seth Lederman Chief Executive Officer Thank you, Deborah, and good morning, everyone. Today, we are reporting our third quarter financial results and operational highlights. Slide 3 outlines our progress in advancing TONMYA's commercial business and priority clinical programs. TONMYA third quarter net sales totaled approximately $15 million, increasing 37% quarter-over-quarter. Previously signed payer agreements contributed to third quarter sales. We have also begun to see promising performance growth since our expanded sales force entered the field on September 1. These positive trends are continuing into the fourth quarter. We remain encouraged by TONMYA's trajectory. With our larger sales force and growing sales, we believe we're well positioned to create value by improving the treatment of fibromyalgia and reinvigorating this market. On October 1, 2026, we received notice from Dr. Reddy's Laboratories that it had filed an abbreviated new drug application, or ANDA, Paragraph IV patent certification for TONMYA. Generic challenges are common in the life cycle of an approved drug. We will vigorously defend and enforce our TONMYA intellectual property rights against infringement. As we prioritize TONMYA's growth, we are also advancing key research and development programs.

    Frequently Asked Questions About TNXP

    When is Tonix Pharmaceuticals Holding's next earnings date?

    Tonix Pharmaceuticals Holding's next earnings report is expected for Mar 10, 2027.

    Did TNXP beat earnings estimates last quarter?

    No. Tonix Pharmaceuticals Holding reported EPS of -$2.89 for the quarter ended Sep 30, 2026, below the -$2.51 estimate by 15.14%.

    What EPS do analysts expect from TNXP next quarter?

    The consensus EPS estimate for Tonix Pharmaceuticals Holding for the quarter ending Dec 31, 2026 is -$2.41 from 8 analysts, with estimates from -$2.45 to -$2.39.

    How often does TNXP beat earnings estimates?

    Tonix Pharmaceuticals Holding beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -40.99%.